Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

678
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
678
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

726
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
726
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

961
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
961

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Living with Legacy: Outcomes and Future Implications for Offspring of Patients with MEN1.

Journal of the ASEAN Federation of Endocrine Societies·2026
Same author

Association of Driver Oncogenic Alterations with SUVmax, Preoperative Serum Calcium, and Smoking Status in Surgically Resected Non-Small-Cell Lung Cancer: A Retrospective Single-Center Study.

Journal of clinical medicine·2026
Same author

Germline Genetic Testing in Breast and Gynecologic Cancers: Evaluating Age at Diagnosis as a Determinant.

Cancers·2026
Same author

Is preoperative adrenoceptor blockade necessary in patients with paraganglioma?

Endocrine-related cancer·2026
Same author

Challenges and Limitations in Molecular Testing of Resected Non-Small Cell Lung Cancer Specimens.

Current issues in molecular biology·2026
Same author

Fulzerasib plus cetuximab in first-line KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.

The Lancet. Oncology·2026
Same journal

Unveiling the role of aldosterone in metabolic dysfunction-associated steatotic liver disease.

Reviews in endocrine & metabolic disorders·2026
Same journal

Prenatal and postnatal maternal obesity and their associations with child nutrition and weight outcomes: A systematic review.

Reviews in endocrine & metabolic disorders·2026
Same journal

Correction: Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Reviews in endocrine & metabolic disorders·2026
Same journal

An elusive link between blood measures of advanced glycation end products and their receptors and cognitive impairment syndromes in people with diabetes: A scoping review.

Reviews in endocrine & metabolic disorders·2026
Same journal

Functional pituitary adenoma imaging.

Reviews in endocrine & metabolic disorders·2026
Same journal

Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis.

Reviews in endocrine & metabolic disorders·2026
See all related articles

Related Experiment Video

Updated: Feb 23, 2026

Electrochemotherapy of Tumours
03:57

Electrochemotherapy of Tumours

Published on: December 15, 2008

25.1K

Chemotherapy in NETs: When and how.

Anna Angelousi1, Gregory Kaltsas2,3, Anna Koumarianou4

  • 1Department of Pathophysiology, Endocrine Oncology Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece. a.angelousi@gmail.com.

Reviews in Endocrine & Metabolic Disorders
|September 12, 2017
PubMed
Summary
This summary is machine-generated.

Chemotherapy, including temozolomide (TMZ), offers treatment options for neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs) when surgery isn't feasible. Research is ongoing to define its role, especially for advanced or metastatic NETs.

Keywords:
ChemotherapyNeuroendocrine cancerNeuroendocrine tumoursRadiopeptidesTemozolomide

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats
06:32

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

27.8K

Related Experiment Videos

Last Updated: Feb 23, 2026

Electrochemotherapy of Tumours
03:57

Electrochemotherapy of Tumours

Published on: December 15, 2008

25.1K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats
06:32

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

27.8K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Neuroendocrine tumours (NETs) vary in aggressiveness, from indolent well-differentiated types to aggressive poorly differentiated neuroendocrine carcinomas (NECs).
  • Surgery is curative for NETs but not always feasible, necessitating alternative therapies like chemotherapy.

Purpose of the Study:

  • To review the current role and evolving applications of chemotherapy in managing neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs).
  • To discuss the efficacy and tolerability of different chemotherapy regimens, including streptozotocin (STZ) and temozolomide (TMZ).

Main Methods:

  • Review of existing literature on chemotherapy use in various subtypes of NETs and NECs.
  • Analysis of treatment guidelines and emerging data for different grades and origins of neuroendocrine malignancies.

Main Results:

  • Streptozotocin (STZ)-based regimens are used for well-to-moderately differentiated (G1-G2) NETs, while platinum-based chemotherapy is recommended for poorly differentiated grade 3 (G3) NECs.
  • Temozolomide (TMZ)-based chemotherapy shows promise as a better-tolerated alternative to STZ for pancreatic NETs (pNETs) and may benefit G3 NETs and intestinal NETs.
  • Chemotherapy is generally reserved for advanced, metastatic, or progressive NETs, particularly after failure of first-line treatments like somatostatin analogues.

Conclusions:

  • Chemotherapy, with a growing role for temozolomide (TMZ), provides essential treatment options for advanced or metastatic neuroendocrine tumours (NETs) and neuroendocrine carcinomas (NECs).
  • Further prospective randomized studies are needed to solidify the role of chemotherapy within the broader therapeutic landscape of NETs, alongside other emerging treatments.